MGC Pharmaceuticals (LON: MXC), a publicly-traded cannabis company, recently finalized pre-clinical trial research of cannabinoids as a potential treatment for glioblastoma, an aggressive brain cancer. The results were positive, reported CityA.M.
The European-based bio-pharma company specializing in the production and development of phytomedicines said that the three-year in-vitro trial delivered “outstanding results.”
